SEC Form 4 · accession 0001140361-15-020981
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Apr 30, 2015
Accepted (ET)
May 19, 2015 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 30, 2015 | A | 88 | $51.2635 | A | 79,366 | D | |
| Common Stock | May 15, 2015 | F | 1,722 | $122.78 | D | 77,644 | D | |
| Common StockF2,F3 | May 18, 2015 | S | 2,059 | $124.7717 | A | 75,585 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person is reporting the purchase of shares of the issuer's Employee Stock Purchase Plan ("ESPP"), for the purchase period of November 1, 2014 to April 30, 2015.
- F2Trade made pursuant to a 10b5-1 plan executed on March 11, 2015.
- F3The price in column 4 is a weighted average price. The price actually received ranged from $122.00 to $125.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.